Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment

(2015) E. Ann Gormley et al.   JOURNAL OF UROLOGY

A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy

(2014) Holly L. Peay et al.   CLINICAL THERAPEUTICS

Defining and Managing Overactive Bladder: Disagreement Among the Experts

(2013) Una J. Lee et al.   UROLOGY

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

(2013) F. Reed Johnson et al.   VALUE IN HEALTH

Patient-Reported Side Effects of Intradetrusor Botulinum Toxin Type A for Idiopathic Overactive Bladder Syndrome

(2011) Ricarda M. Bauer et al.   UROLOGIA INTERNATIONALIS

Satisfaction and Patient Experience With Sacral Neuromodulation: Results of a Single Center Sample Survey

(2010) Randall K. Leong et al.   JOURNAL OF UROLOGY

Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling

(2010) Terry N Flynn   Expert Review of Pharmacoeconomics & Outcomes Research